Key takeaways:

Adults with obesity lost more body weight with once-daily orforglipron vs. placebo.

Orforglipron’s safety profile was similar to other GLP-1 medications.

Full data from ATTAIN-1 will be presented in September.

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results from the phase 3 ATTAIN-1 trial.

As Healio previously reported , orforglipron (Eli Lilly), a once-daily oral GLP-1, induced greater reductions in HbA1c than placebo at 40 weeks for adults with type 2 diabetes in the ACHIEVE-1 trial.

Adults with obesity lost significantly more weight with orforglipron than placebo in a phase 3 trial. Image: Adobe Stock

In ATTAIN-1, researchers assessed the efficacy of the medication in a cohort of 3,127

See Full Page